Angiotensin receptor blockers, FDA-approved for hypertension, have anticonvulsant effects in rats (284–286) and decrease incidence of epilepsy in humans (287), while decreasing CSF t-tau and p-tau in MCI patients (288) and improving cognition in hypertensive older adults with early executive impairment (289) and prodromal AD (290). The gene discussed is MAPT; the disease is epilepsy.